DIAN Diagnostics stated on the investor interaction platform on July 17 that it has a series of auxiliary diagnostic software systems with independent intellectual property rights. The company also claimed that it not only explores AI technology’s application in medical tests (such as report interpretation, knowledge map optimization, clinical decision-making assistance, etc.) with a couple of medical institutions, academic leaders, and technology companies, and meantime it has jointly created a company based on AI inspection and pathology CRO (Yicai Technology) with the former IBM global data analysis team, and some of the products have obtained second-class certificates and overseas CE certificates, among which the pathological processing software of cervical cancer cells is going for the first three types of certificates in the field of ICL. Since February this year, with the recovery of out-of-town medical treatment and outpatient visits, the year-on-year and month-on-month growth trend of diagnostic service revenue.

From NetEase

July 17th, 2023